The treatment plan of 1 patient with HER-2 breast cancer reported in this paper is the 1st time to use the combination of: internal administration of TCM associated with HER-2 dual-targeted therapy and chemotherapy treatment, and also reflects the feasibility and safety of this plan. The gene discussed is ERBB2; the disease is breast cancer.